SHARE:  
Join Our Email List
White Paper | Oligonucleotide Therapeutics
Oligonucleotide-based therapeutics are set to transform the landscape of treatable human disease. While creating oligonucleotide therapeutics is theoretically as straightforward as a sequence of chemical building blocks, designing effective treatments for clinical applications involves understanding both the chemistry and biology of nucleic acids. In our newest white paper, learn about recent advances in chemical modifications for oligonucleotide therapeutics that improve stability and selectivity, biological screening assay approaches, and bioanalytical platforms that address the challenges of quantifying oligonucleotides. 

Latest Sciences | Publications
Discovery and Characterization of Proteolysis Targeting Chimeras
Tissue transglutaminase (TG2) is a multifunctional enzyme activated in several pathological conditions, including cancer. WuXi AppTec recently contributed to a study which used a targeted protein degradation strategy to abolish TG2's myriad of functions. The authors synthesized and characterized a series of VHL-based degraders that reduce TG2 in ovarian cancer cells in a proteasome-dependent manner.
Discovery of Novel GST Inhibitors Identified from a DNA-Encoded Library
WuXi AppTec scientists recently contributed to a study which led to the discovery and optimization of a novel series of GST inhibitors. The authors used affinity mediated DEL selection against a privileged scaffold to identify a compound with potent inhibition against glutathione S-transferase Mu 2.
SAR studies, coupled with X-ray crystallography and structural analysis, revealed that the binding mode of this inhibitor is quite different from known GSH-like compounds.
Spotlight on Services | Oncolytic Virus Platform
Oncolytic Virus Services
Oncolytic viruses (OVs) are emerging as a promising therapeutic approach for treating cancer. OVs are capable of both tumor-specific cell lysis and immune stimulation and can be optimized for enhanced tumor selectivity. 
WuXi AppTec offers a comprehensive platform of OV-related services, including virus engineering and validation, immune profiling and lysis assays, tumor cell selectivity, in vivo efficacy and safety studies, as well as bio-distribution and viral shedding assays.  
On-Demand Webinar | Emerging Modalities in Drug Discovery
Now available to view on demand! Learn about the challenges in developing next-generation therapeutics based on new modalities such as targeted protein degraders, targeted covalent inhibitors, and nucleic acids. In this on-demand webinar, our expert speaker discusses the resources available when using a global open access platform, and the latest advances and technologies for addressing the complexities in designing, synthesizing, and optimizing these molecules.  
Latest Sciences | Technology-Focused Articles
DELvision:
Improving Data-Driven Drug Discovery
Read our newest article introducing DELvision, a powerful DNA encoded library (DEL)-based toolset for AIphaFold-assisted drug discovery and target sciences. DELvision offers high quality, off-the-shelf DEL screening data covering thousands of targets. In addition, DELvision is positioned to provide valuable training data for machine learning of structure-activity relationships.
As Reported in Business Wire:
DNA-Encoded Libraries (DELs) and NanoBRET Target Engagement Assays Accelerate Drug Discovery
Read news coverage of our recent study (published in Cell Chemical Biology) demonstrating how the combination of DELs and NanoBRET target engagement technology can accelerate early-stage drug discovery. As quoted in this article: “The authors demonstrate that DELs can benefit chemical biologists who require verification of live cell target engagement for their protein of interest."
Upcoming Webinar | Recent Advances in Peptide Drug Discovery
Join WuXi AppTec on September 21st as we showcase the use of DNA encoded libraries (DEL) to discover peptide macrocycles that disrupt protein-protein interactions and provide a case study using the oncoprotein murine double minute 2 (MDM2). We will also highlight the advantages of DEL compared to other methods, which includes the ability to use unnatural amino acids. DEL can provide greater chemical diversity with smaller ring sizes, which facilitates subsequent hit development as it pertains to beneficial PK properties.
Upcoming Events | DOT 2023 and Merck Technology Symposium
Discovery On Target 2023
Join us in Boston for this year's Discovery On Target Conference. We are proud to have our Sr. VP, Tao Guo, and our Sr. Director, Wenji Su, provide thought leadership presentations on advances in RNA-targeting small molecules and targeted protein degradation. Don't forget to stop by booth 411 and get your questions answered by one of our experts! 
Merck Technology Symposium 2023
Join us at this year's Merck Technology Symposium in Holmdel NJ. Our Sr. Director, Dr. Jason Deng, will present a talk entitled "Discovery of a Neutral MDM2-p53 Inhibitor with DNA encoded Macrocyclic Libraries" during the modalities program track, in Theater 4 on Day 2. And don't forget to stop by booth 507 and get your questions answered by one of our experts!